Chronic wounds, including diabetic, venous and pressure ulcers, affect up to 6.5 million Americans. These non-healing wounds reduce patients’ quality of life through pain, infection, sepsis, and amputation. Many chronic wounds occur in patients with comorbidities that makes treatment even more difficult. Not only are current solutions ineffective, but they can also be expensive and potentially carcinogenic. Nitrix is a new, low-cost biomaterial that treats the root causes of chronic wounds – inflammation and poor vascularization – to promote healing.
Description
Removing the cells from mammalian tissue leaves behind a structural support scaffold of proteins and lipids known as the extracellular matrix (ECM). With Nitrix, the decellularization process not only clears out cells but also activates the ECM, imbuing it with regenerative properties. Testing in vitro reveals that Nitrix enhances antioxidant, anti-inflammatory, and angiogenic activity in wounded tissue. Compared to other ECM devices, Nitrix is no more costly or complicated to produce, and it offers greater healing capabilities.
Applications
· Treating chronic wounds, such as diabetic, venous, or pressure ulcers
· Treating burn wounds
· Large-scale reconstructions
· Hernias
· Myocardial infarction
· Stroke
· Peripheral nerve repair
· Vascular repair
Advantages
· Low cost
· Off-the-shelf accessibility
· Can be cut to size, easy to handle and suture
· Increases antioxidant, anti-inflammatory, and angiogenic activity in wound tissue
Invention Readiness
In vivo pilot studies ongoing.
IP Status
https://patents.google.com/patent/WO2019094734A1
